These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6281694)

  • 1. Caerulein and cholecystokinin octapeptide (CCK-8): sedative and anticonvulsive effects in mice unaffected by the benzodiazepine antagonist Ro 15-1788.
    Zetler G
    Neurosci Lett; 1982 Mar; 28(3):287-90. PubMed ID: 6281694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticonvulsant effects of caerulein, cholecystokinin octapeptide (CCK-8) and diazepam against seizures produced in mice by harman, thiosemicarbazide and isoniazid.
    Zetler G
    Neurosci Lett; 1981 Jul; 24(2):175-80. PubMed ID: 6265841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam.
    Zetler G
    Neuropharmacology; 1983 Jun; 22(6):757-66. PubMed ID: 6310434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceruletide, ceruletide analogues and cholecystokinin octapeptide (CCK-8): effects on motor behaviour, hexobarbital-induced sleep and harman-induced convulsions.
    Zetler G
    Peptides; 1982; 3(4):701-4. PubMed ID: 6291014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convulsions induced by submaximal dose of pentylenetetrazol in mice are antagonized by the benzodiazepine antagonist Ro 15-1788.
    Grecksch G; de Carvalho LP; Venault P; Chapouthier G; Rossier J
    Life Sci; 1983 May; 32(22):2579-84. PubMed ID: 6406779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of hypothermic effect of cholecystokinin by benzodiazepines and a benzodiazepine antagonist, Ro 15-1788, in mice.
    Sugaya K; Matsuda I; Kubota K
    Jpn J Pharmacol; 1985 Oct; 39(2):277-80. PubMed ID: 2868143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic-like effects of ceruletide and cholecystokinin octapeptide: interactions with apomorphine, methylphenidate and picrotoxin.
    Zetler G
    Eur J Pharmacol; 1983 Oct; 94(3-4):261-70. PubMed ID: 6140174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of the anticonvulsant effects of diazepam on amygdaloid-kindled seizures by a specific benzodiazepine antagonist: RO 15-1788.
    Le Gal La Salle G; Feldblum S
    Eur J Pharmacol; 1982 Dec; 86(1):91-3. PubMed ID: 6819154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of antinociceptive effect of cholecystokinin by benzodiazepines and a benzodiazepine antagonist, Ro 15-1788.
    Kubota K; Sugaya K; Matsuda I; Matsuoka Y; Terawaki Y
    Jpn J Pharmacol; 1985 Jan; 37(1):101-5. PubMed ID: 2859382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central effects of ceruletide analogues.
    Zetler G
    Peptides; 1981; 2 Suppl 2():65-9. PubMed ID: 6283499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsant effects of careulein and cholecystokinin octapeptide, compared with those of diazepam.
    Zetler G
    Eur J Pharmacol; 1980 Jul; 65(2-3):297-300. PubMed ID: 6249626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.
    Harro J; Põld M; Vasar E
    Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):62-7. PubMed ID: 2314484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
    Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
    Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine and yohimbine separate the sedation and the ptosis caused by cholecystokinin octapeptide and ceruletide.
    Zetler G
    Eur J Pharmacol; 1984 Jul; 102(2):333-40. PubMed ID: 6090162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception.
    Rattray M; Jordan CC; De Belleroche J
    Eur J Pharmacol; 1988 Jul; 152(1-2):163-6. PubMed ID: 3208830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
    Vasar E; Stephenson JD; Meldrum BS
    Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of central and peripheral anorectic effects of caerulein by L-364,718.
    Leighton GE; Griesbacher T; Hill RG; Hughes J
    Eur J Pharmacol; 1989 Feb; 161(2-3):255-8. PubMed ID: 2721558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cholecystokinin-like peptides on rearing activity and hexobarbital-induced sleep.
    Zetler G
    Eur J Pharmacol; 1980 Aug; 66(1):137-9. PubMed ID: 6250861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8).
    Zetler G
    Neuropharmacology; 1980 May; 19(5):415-22. PubMed ID: 6248810
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of electroshock-induced seizures by cholecystokinin-related peptides in mice.
    Kádár T; Borda L; Zarándi M; Penke B; Kovács K; Telegdy G
    Acta Physiol Hung; 1987; 69(1):43-50. PubMed ID: 3591354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.